BHQ 880

Drug Profile

BHQ 880

Alternative Names: Anti-DKK1 mAb; Anti-DKKK-1 neutralising antibody (BHQ880); BHQ-880

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator MorphoSys; Novartis
  • Class Antibodies; Antineoplastics; Monoclonal antibodies
  • Mechanism of Action DKK1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Multiple myeloma
  • No development reported Solid tumours

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Solid-tumours in USA (IV)
  • 20 Aug 2015 BHQ 880 is still in phase-II development for Multiple myeloma in USA and Europe
  • 01 Nov 2013 Novartis completes a phase II trial in Multiple myeloma (treatment naive, monotherapy) in USA, Germany and France (IV) (NCT01302886)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top